Palmitoylethanolamide for Chronic Inflammatory Pain Conditions
Randomized Placebo-Controlled Trial of Palmitoylethanolamide for Chronic Inflammatory Pain Conditions
Navy Medical Center San Diego
80 participants
Aug 5, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to evaluate if a supplement called palmitoylethanolamide (PEA) is effective in reducing the pain in patients with chronic inflammatory pain conditions. The main question the trial aims to answer is if PEA works better at treating a patients pain and improving their function better than a placebo. Participants will be divided into two equal groups and asked to take either PEA or a placebo for 8 weeks.
Eligibility
Inclusion Criteria1
- Chronic Inflammatory Pain of greater than 3 months duration and greater than or equal to 5/10 intensity that has not responded to other conservative therapies such as rest, ice, compression or other oral medications.
Exclusion Criteria1
- Severe allergy to any specific food component such as nut, egg or soy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
600mg palmitoylethanolamide twice a day
visually identical placebo capsule
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06273462